Dimon and the company have been straightforward in saying this is a beatable form of cancer. Cramer says those who are selling the stock should be aware of similar cases, such as Andrew Grove at Intel (INTC), Robert Benmosche at AIG (AIG) and Warren Buffett at Berkshire Hathaway (BRK.B). Each of those figures said they had treatable forms of cancer, which "is not something you can just kind of blithely say," according to Cramer.
All three of those stocks went up not long after the news broke, as investors realized the truth about the curable cancers. Therefore, Cramer says he would not sell J.P. Morgan in the wake of the Dimon news.
TheStreet Ratings team agrees, as it rates JPMORGAN CHASE & CO as a "buy" with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:
"We rate JPMORGAN CHASE & CO (JPM) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."